REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule MEK 1/2 inhibitor. The platform analyzed cellular models of APC gene loss-the root cause of FAP-to identify compounds ...

The Indira Gandhi International (IGI) Airport in Delhi is expected to meet multiple global parameters to be deemed an international airport hub within the next two years, Videh Kumar Jaipuriar ...

Meta’s answer to DeepSeek is here: Llama 4 launches with long context Scout and Maverick models, and 2T parameter Behemoth on the way!

Polaris 3.0 was developed using extensive feedback from actual patients and their healthcare providers from over 1.85 million patient calls.

SALT LAKE CITY – Recursion, a clinical-stage TechBio company listed on NASDAQ: RXRX, has announced the appointment of two new members to its Board of Directors. Namandjé Bumpus, Ph.D., and ...

Recursion also announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for a Phase 1/2 clinical trial of REC-4539, a potential best-in-class LSD1 ...

Recursion’s study will initially address the recurrent C. diff (up to 175,000 cases in the US per year) population, which costs the healthcare system approximately US$2 billion per year. (US$1=RM4.32) ...

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection REC-3964 ...

This study presents a grey-box recursive identification technique to estimate key parameters in a mineral flotation process across two scenarios. The method is applied to a nonlinear physics-based ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2024 Earnings Call Transcript August 9, 2024 Chris Gibson: Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, delighted to be ...

SALT LAKE CITY - Recursion, a clinical stage TechBio company, has received clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1/2 clinical trial of its new chemical entity, REC ...